Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes diagnostic and therapeutic molecular nuclear medicine, or MNM, products.

AAA is at the forefront of developing predictive, preventive and personalized tools and procedures that have the potential to radically transform healthcare. Our path to accomplishing this goal is by merging therapeuti... more >

Latest Newsmore >
12/07/17
Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
SAINT-GENIS-POUILLY, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that a direct and indirect subsidiary of Novartis AG (NYSE:NVS), Novartis Groupe France S.A., a société anonyme organized under the laws of France (“Purchaser”), has commenced a cash tender offer to purchase all of the outstanding ordinary shares, nominal value €0.10 per share (each, an “Ordinary Sh... 
12/05/17
Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis
SAINT-GENIS-POUILLY, France, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that its Board of Directors, following the completion of the information and consultation of the Company’s works council, has (i) determined that the transactions contemplated in the Memorandum of Understanding entered into with Novartis AG (NYSE:NVS) on October 28, 2017 (the “Memorandum of Understa... 
11/17/17
Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017
$3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETs Recent Highlights: Sales for the third quarter of 2017 increased 39% compared to the third quarter of 2016 NETSPOT® unit sales per month increased 14% (from 915 to 1040) from June to September 2017 Entered into a Memorandum of Understanding with Novartis, pursuant to which Novartis proposes to make a $3.9 billion cash tender offer to acquire all the outs... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources